public health implications are different from tuberculosis.
Disease caused by M kansasii and other environmental mycobacteria is not considered to be transmissible and is therefore not notifiable. No contact tracing is required.
Chronic pulmonary disease caused by M kansasii can range from mild, self-limiting, trivial disease to severe progressive and fatal disease with extensive cavitation. On direct smear M kansasii cannot be distinguished from M tuberculosis.'" Only when culture results are available three weeks or more after specimens have been taken will it be possible to distinguish between the bacillus causing tuberculosis and one that does not. In the meantime the patient will probably have been started on antituberculosis chemotherapy comprising isoniazid, rifampicin, and pyrazinamide.
Most strains of M kansasii are resistant to isoniazid and pyrazinamide. Valuable time may therefore have been lost treating with only a single effective agent with the theoretical possibility of resulting resistance to rifampicin, although this appears to occur rarely if at all. Fortunately M kansasii is almost always sensitive to ethambutol, so the addition of this very useful fourth drug should be considered if infection with an environmental mycobacterium is considered likely.
Whereas drug sensitive tuberculosis almost invariably responds to six months of chemotherapy, diseases caused by the environmental mycobacteria including M kansasii have traditionally been treated for one or two years." 12 A three drug regimen including a potentially toxic dose of isoniazid of 600 mg/day has been recommended.'3 The Research Committee of the British Thoracic Society'4 has conducted a prospective study of the treatment of M kansasii infection in the UK and the results, reported in this issue of Thorax, suggest that "short course" chemotherapy in the form of nine months of rifampicin and ethambutol is now possible.
About 50 patients with two or more isolates of M kansasii, indicating the presence of clinically significant disease, are currently reported to the Mycobacterium Reference Unit of the PHLS annually. Despite the increase in HIV infection this seems to have altered little in the past decade. It is the M avium-intracellulare complex which is implicated as the HIV related opportunist mycobacterium in this country, although M kansasii may be increasing in the USA because of HIV infection.9 To do any form of randomised controlled trial of the chemotherapy of M kansasii in the UK would therefore be impractical. Members of the British Thoracic Society and the Mycobacteria Subcommittee of the BTS Research Committee are to be congratulated on providing useful information on chemotherapy from the patients available in a prospective study: 173 over a period of four years.
Two facts which emerge from this study require further explanation. Firstly, there was a 9 7% relapse rate; for M tuberculosis this would be regarded as unacceptably high. As the authors point out this is higher than in other studies using longer periods of treatment and sometimes including isoniazid." On the other hand, the studies quoted had shorter periods of follow up. The authors' suggestion that three of the patients in this study who 
